The earnings call highlighted significant achievements such as double-digit revenue growth, strategic advancements in biosimilars, and a strong financial position, which were offset by challenges in the U.S. generics segment, gross margin declines, and regulatory inspection issues. The sentiment is balanced with both positive and negative aspects.

Company Guidance -

Q2 2026

During the Q1 FY '26 earnings call of Dr. Reddy's Laboratories, several key financial metrics were highlighted. The company reported consolidated revenues of INR 8,545 crores (USD 997 million), marking an 11% year-over-year growth. The EBITDA margin was reported at 26.7%, slightly above the company's aspiration of 25%. Gross profit margin for the quarter was 56.9%, with a decrease of 350 basis points year-over-year but an improvement of 134 basis points sequentially. The SG&A expenses increased by 13% year-over-year, accounting for 30% of sales. R&D expenses were INR 624 crores (USD 73 million), making up 7.3% of sales. The company reported a profit before tax of INR 1,905 crores (USD 222 million), with an effective tax rate of 25.9%. Profit after tax stood at INR 1,419 crores (USD 166 million), representing a 2% year-over-year growth. Additionally, the company maintained a net cash surplus of INR 2,922 crores (USD 341 million) as of June 30, 2025, and generated free cash flow of INR 433 crores (USD 51 million) during the quarter.

Double-Digit Revenue Growth

Dr. Reddy's reported a double-digit revenue growth with consolidated revenues of INR 8,545 crores (USD 997 million), an 11% increase year-over-year.

EBITDA Margin Improvement

The company achieved an EBITDA margin of 26.7%, surpassing the aspiration of 25%.

Strategic Advancements in Biosimilars

The biosimilar business gained momentum with a strategic collaboration with Alvotech for pembrolizumab and progress in key pipeline programs like semaglutide and abatacept.

Strong Financial Position

Dr. Reddy's closed the quarter with a net cash surplus of USD 341 million, reinforcing its strong balance sheet position.

India Business Growth

The India business delivered a double-digit year-on-year growth of 11%, driven by new product contributions and pricing.

Recognition for Sustainability Efforts

Dr. Reddy's received an A rating in the Carbon Disclosure Project (CDP) for climate, making it the only Indian pharmaceutical company with this score.

Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IN:DRREDDY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 24, 2025	2026 (Q2)	17.59 / -	15.04	―	―	―
Jul 23, 2025	2026 (Q1)	18.38 / 17.02	16.692	1.97% (+0.33)	―	―
May 09, 2025	2025 (Q4)	18.18 / 19.11	15.67	21.95% (+3.44)	―	―
Jan 23, 2025	2025 (Q3)	17.91 / 16.94	16.536	2.44% (+0.40)	―	―
Nov 05, 2024	2025 (Q2)	17.33 / 15.04	17.756	-15.30% (-2.72)	―	―
Jul 27, 2024	2025 (Q1)	16.06 / 16.69	16.844	-0.90% (-0.15)	―	―
May 07, 2024	2024 (Q4)	14.70 / 15.67	11.524	35.98% (+4.15)	―	―
Jan 30, 2024	2024 (Q3)	14.68 / 16.54	14.99	10.31% (+1.55)	―	―
Oct 27, 2023	2024 (Q2)	14.49 / 17.76	13.378	32.73% (+4.38)	―	―
Jul 26, 2023	2024 (Q1)	12.68 / 16.84	14.28	17.96% (+2.56)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IN:DRREDDY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 23, 2025	₹1240.40	₹1247.55	+0.58%
May 09, 2025	₹1141.46	₹1149.11	+0.67%
Jan 23, 2025	₹1288.13	₹1281.22	-0.54%
Nov 05, 2024	₹1259.96	₹1264.53	+0.36%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) report earnings?

Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) is schdueled to report earning on Oct 24, 2025, Before Open (Confirmed).

What is Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) earnings time?

Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) earnings time is at Oct 24, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Dr. Reddy's Laboratories Ltd. stock?

The P/E ratio of Dr. Reddy's Laboratories Ltd. is N/A.

What is IN:DRREDDY EPS forecast?

IN:DRREDDY EPS forecast for the fiscal quarter 2026 (Q2) is 17.59.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing